DOJ in­ves­ti­gat­ing Bausch Health over plaque pso­ri­a­sis drug mar­ket­ing — re­port

Just a few weeks af­ter Bausch Health ran afoul of the FDA’s drug mar­ket­ing po­lice, a new re­port has emerged that the com­pa­ny has been un­der in­ves­ti­ga­tion by the De­part­ment of Jus­tice since at least last June.

STAT News re­port­ed Bausch cir­cu­lat­ed doc­u­ments among its le­gal team on June 14, 2021, out­lin­ing its strat­e­gy to com­ply with the DOJ’s re­quest. The probe, known as a civ­il in­ves­tiga­tive de­mand, aims to look at whether Bausch pro­mot­ed three plaque pso­ri­a­sis drugs — as well as a fun­gal treat­ment — in ways not in­tend­ed for use.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.